New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HINDVyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.
- Revenue
- +67.6%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.20
0.25
−17.24%
Follow HIND
Alert me
Vyome Holdings, Inc. (HIND) P/E ratio
Vyome Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LEXX Lexaria Bioscience Corp. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. | n/m |
| BIVI BioVie Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.1× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 21.7× |
| Market median | 16.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)